Further, disruption of GM-CSF signaling by either GM-CSF autoantibodies as occurs in autoimmune PAP10–12 or by CSF2RA or CSF2RB mutations as occurs in hereditary PAP13–15 mediates pathogenesis in > 90% of PAP patients. The gene discussed is CSF2; the disease is pulmonary alveolar proteinosis.